Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorVivek Jain
About this trial
This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure (CPAP) device while sleeping decreasing some of the harmful effects of low oxygen in people with sleep apnea.
This study will last 35 nights and involves spending three nights in the sleep lab at George Washington University. There are no additional costs to participants and no compensation for being involved in the study.
Eligibility criteria
Qualifiers
Men or women 18 years of age or older.
Disqualifiers
subjects not willing to or otherwise unable to use CPAP for treatment of OSA.
Presence of other sleep disorders
Pregnant or breastfeeding women
Women of child-bearing age (WOCBA) not willing or unable to use an accepted method to avoid pregnancy for the entire duration of the study
Trial design
Treatments tested in this trial
- Oxytocin
- Placebo
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Vivek Jain
Lead sponsor
George Washington University
Sponsor institution
George Washington University
Collaborator
Source ClinicalTrials.gov